Researchers from the Johns Hopkins Bloomberg School of Public Health supported the first blood center in the U.S. to be granted full FDA approval to provide convalescent plasma to immunocompromised ...
Please provide your email address to receive an email when new articles are posted on . Compared with placebo, convalescent plasma with neutralizing anti-SARS-CoV-2 antibodies showed no improvement in ...
Convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover, according to a national clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results